<DOC>
	<DOC>NCT00092274</DOC>
	<brief_summary>The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).</brief_summary>
	<brief_title>Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Relapsed or refractory follicular lymphoma grade III Tumor verified to be CD20 positive CT scan showing demarcated lesions Previous treatment with rituximab resulting in less than partial response Previous radioimmunotherapy Previous stem cell transplantation Received the following treatments within 4 weeks prior to entering this study: 1. Anticancer therapy 2. Glucocorticosteroids unless less than 10 mg prednisolone/day 3. Radiotherapy Received Mitomycin C or Nitrosoureas within 6 weeks prior to entering this trial HIV positivity Hepatitis B or hepatitis C Uncontrolled or chronic bacterial, fungal or viral infection Other cancer diseases, except certain skin cancers, cervix cancer and breast cancer Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases WHO performance status of 3 or 4 If you are participating in another trial with a different new drug 4 weeks before you enter this trial Current participation in any other clinical study Pregnant or breastfeeding women Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Non Hodgkin´s Lymphoma</keyword>
</DOC>